JP2014500002A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014500002A5 JP2014500002A5 JP2013529285A JP2013529285A JP2014500002A5 JP 2014500002 A5 JP2014500002 A5 JP 2014500002A5 JP 2013529285 A JP2013529285 A JP 2013529285A JP 2013529285 A JP2013529285 A JP 2013529285A JP 2014500002 A5 JP2014500002 A5 JP 2014500002A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- tcr
- cancer
- isolated
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38493110P | 2010-09-21 | 2010-09-21 | |
| US61/384,931 | 2010-09-21 | ||
| PCT/US2011/051537 WO2012040012A1 (en) | 2010-09-21 | 2011-09-14 | Anti-ssx-2 t cell receptors and related materials and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017082965A Division JP2017158567A (ja) | 2010-09-21 | 2017-04-19 | 抗ｓｓｘ−２ ｔ細胞受容体及び関連材料並びに使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014500002A JP2014500002A (ja) | 2014-01-09 |
| JP2014500002A5 true JP2014500002A5 (cg-RX-API-DMAC7.html) | 2014-09-11 |
| JP6133209B2 JP6133209B2 (ja) | 2017-05-24 |
Family
ID=44720141
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013529285A Active JP6133209B2 (ja) | 2010-09-21 | 2011-09-14 | 抗ｓｓｘ−２ｔ細胞受容体及び関連材料並びに使用方法 |
| JP2017082965A Pending JP2017158567A (ja) | 2010-09-21 | 2017-04-19 | 抗ｓｓｘ−２ ｔ細胞受容体及び関連材料並びに使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017082965A Pending JP2017158567A (ja) | 2010-09-21 | 2017-04-19 | 抗ｓｓｘ−２ ｔ細胞受容体及び関連材料並びに使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US9345748B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3533802B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6133209B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN103124740B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2011305817B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2811788C (cg-RX-API-DMAC7.html) |
| ES (2) | ES2876176T3 (cg-RX-API-DMAC7.html) |
| IL (3) | IL225063A (cg-RX-API-DMAC7.html) |
| PT (2) | PT2619223T (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012040012A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2876176T3 (es) * | 2010-09-21 | 2021-11-12 | The Us Secretary Department Of Health And Human Services Office Of Technology Transfer National Inst | Receptores de células T anti-SSX-2 y materiales relacionados y métodos de uso |
| CA2853687A1 (en) | 2011-11-03 | 2013-05-10 | Tolera Therapeutics, Inc | Antibody and methods for selective inhibition of t-cell responses |
| US20130273089A1 (en) | 2011-11-03 | 2013-10-17 | Tolera Therapeutics, Inc. | Antibody and methods for selective inhibition of t-cell responses |
| US10316289B2 (en) | 2012-09-06 | 2019-06-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing T memory stem cell populations |
| WO2014100615A1 (en) | 2012-12-20 | 2014-06-26 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| ES2745472T3 (es) | 2013-07-15 | 2020-03-02 | The U S A As Represented By The Secretary Department Of Health And Human Services Office Of Tech Tra | Receptores de células T anti-virus del papiloma humano 16 E6 |
| US10654907B2 (en) | 2014-01-29 | 2020-05-19 | University Health Network | Methods and compositions for producing a cell expressing a T cell receptor |
| CA2955984A1 (en) | 2014-07-22 | 2016-01-28 | The University Of Notre Dame Du Lac | Molecular constructs and uses thereof |
| SG11201703309PA (en) * | 2014-10-31 | 2017-05-30 | Baylor College Medicine | Survivin specific t-cell receptor targeting tumor but not t cells |
| EP4653013A2 (en) * | 2014-10-31 | 2025-11-26 | The Trustees of the University of Pennsylvania | Methods and compositions for modified t cells |
| US11098283B2 (en) | 2015-08-25 | 2021-08-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cells modified to overexpress c-Myb |
| CA2998270A1 (en) * | 2015-10-01 | 2017-04-06 | Ospedale San Raffaele S.R.L. | Tcr and uses thereof |
| WO2017070042A1 (en) | 2015-10-20 | 2017-04-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing t cell populations using akt inhibitors |
| WO2017139199A1 (en) | 2016-02-10 | 2017-08-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inducible arginase |
| EP3439675A4 (en) | 2016-04-08 | 2019-12-18 | Purdue Research Foundation | METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY |
| ES2906795T3 (es) * | 2016-04-26 | 2022-04-20 | Us Health | Receptores de células T anti-KK-LC-1 |
| EP3516045A1 (en) | 2016-09-23 | 2019-07-31 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Methods of preparing an isolated population of dendritic cells and methods of treating cancer using same |
| NZ754365A (en) | 2016-12-08 | 2022-02-25 | Immatics Biotechnologies Gmbh | Novel t cell receptors and immune therapy using the same |
| EP3555266B1 (en) | 2016-12-13 | 2023-11-15 | The United States of America, as Represented by The Secretary, Department of Health and Human Services | Methods of preparing an isolated or purified population of thymic emigrant cells and methods of treatment using same |
| EP3579870A4 (en) | 2017-02-07 | 2020-12-30 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | PHOSPHOLIPID ETHER (PLE) T CAR-LYMPHOCYTE TUMOR (CTCT) TARGETING AGENTS |
| US20190359678A1 (en) * | 2017-02-09 | 2019-11-28 | The Regents Of The University Of California | Chimeric t cell antigen receptors and methods of use thereof |
| CN110582288B (zh) | 2017-02-28 | 2024-09-20 | 恩多塞特公司 | 用于car t细胞疗法的组合物和方法 |
| KR102609624B1 (ko) | 2017-03-15 | 2023-12-05 | 옥스포드 바이오메디카(유케이) 리미티드 | 방법 |
| EP3635098B1 (en) | 2017-06-05 | 2021-09-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T-cells modified to overexpress phf19 |
| CA3077595A1 (en) | 2017-10-05 | 2019-04-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for diagnosing, monitoring and treating neurological diseases and disorders |
| AU2018346719A1 (en) | 2017-10-06 | 2020-04-23 | Oslo Universitetssykehus Hf | Chimeric antigen receptors |
| WO2019075055A1 (en) | 2017-10-11 | 2019-04-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | METHODS FOR PRODUCING T-CELL POPULATIONS USING P38 MAPK INHIBITORS |
| EP3720478A1 (en) * | 2017-12-04 | 2020-10-14 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Hla class i-restricted t cell receptors against mutated ras |
| CN112055595B (zh) | 2018-01-22 | 2024-12-17 | 恩多塞特公司 | Car t细胞的使用方法 |
| CA3090089A1 (en) | 2018-02-06 | 2019-08-15 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors |
| US20210052647A1 (en) | 2018-02-09 | 2021-02-25 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Tethered interleukin-15 and interleukin-21 |
| JP7568224B2 (ja) | 2018-02-23 | 2024-10-16 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞療法のための配列決定法 |
| CN112236447B (zh) * | 2018-04-19 | 2023-10-20 | 得克萨斯州大学系统董事会 | 具有mage-b2特异性的t细胞受体及其用途 |
| US12415845B2 (en) | 2018-04-24 | 2025-09-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing T cell populations using hydroxycitric acid and/or a salt thereof |
| WO2019241315A1 (en) | 2018-06-12 | 2019-12-19 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| CN110950949B (zh) * | 2018-09-26 | 2022-04-05 | 香雪生命科学技术（广东）有限公司 | 一种识别ssx2抗原的t细胞受体 |
| AU2020298326A1 (en) * | 2019-06-21 | 2022-01-27 | Children's National Medical Center | Methods and composition for a binding molecule targeting cancer cells expressing SSX2 peptide 41-49 in HLA-A*0201 context |
| EP3990491A1 (en) | 2019-06-26 | 2022-05-04 | Massachusetts Institute of Technology | Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof |
| WO2021016887A1 (zh) * | 2019-07-30 | 2021-02-04 | 广东香雪精准医疗技术有限公司 | 识别ssx2抗原短肽的t细胞受体 |
| CN112409474B (zh) * | 2019-08-23 | 2023-02-28 | 香雪生命科学技术（广东）有限公司 | 一种识别ssx2抗原的高亲和力tcr |
| CN112442119B (zh) * | 2019-09-05 | 2023-02-24 | 香雪生命科学技术（广东）有限公司 | 一种识别ssx2的高亲和力t细胞受体 |
| WO2021061648A1 (en) | 2019-09-23 | 2021-04-01 | Massachusetts Institute Of Technology | Methods and compositions for stimulation of endogenous t cell responses |
| MX2022011080A (es) | 2020-03-10 | 2023-01-04 | Massachusetts Inst Technology | Metodos para generar celulas nk de tipo memoria modificadas y composiciones de las mismas. |
| WO2021221783A1 (en) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof |
| US12433954B2 (en) | 2020-05-01 | 2025-10-07 | Massachusetts Institute Of Technology | Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs |
| AU2021341969A1 (en) | 2020-09-08 | 2023-03-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell phenotypes associated with response to adoptive cell therapy |
| EP4243937A2 (en) | 2020-11-13 | 2023-09-20 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Enhanced antigen reactivity of immune cells expressing a mutant non-signaling cd3 zeta chain |
| JP2023553815A (ja) | 2020-11-24 | 2023-12-26 | ライエル・イミュノファーマ・インコーポレイテッド | 幼若化したｔ細胞を作製する方法、それを含む組成物、及びその使用方法 |
| CN115819555A (zh) * | 2021-09-17 | 2023-03-21 | 香雪生命科学技术（广东）有限公司 | 一种识别ssx2的高亲和力tcr |
| CA3241588A1 (en) | 2021-12-31 | 2023-07-06 | Sri Krishna | T cell therapy with vaccination as a combination immunotherapy against cancer |
| WO2025160480A1 (en) | 2024-01-26 | 2025-07-31 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Enhanced tumor reactivity of t cells lacking sit1, lax1, or trat1 |
| WO2025250587A1 (en) | 2024-05-29 | 2025-12-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Drug-regulatable, inducible cytokine expression |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4450150A (en) | 1973-05-17 | 1984-05-22 | Arthur D. Little, Inc. | Biodegradable, implantable drug delivery depots, and method for preparing and using the same |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| IN165717B (cg-RX-API-DMAC7.html) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| JP3266311B2 (ja) | 1991-05-02 | 2002-03-18 | 生化学工業株式会社 | 新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤 |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| US20020197266A1 (en) | 2000-02-08 | 2002-12-26 | Waldemar Debinski | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
| EP1227321A1 (en) * | 2000-12-28 | 2002-07-31 | Institut für Bioanalytik GmbH | Reversible MHC multimer staining for functional purification of antigen-specific T cells |
| MXPA05002455A (es) * | 2002-09-06 | 2005-06-03 | Mannkind Corp | Secuencias de epitopes. |
| US20060194211A1 (en) * | 2003-04-29 | 2006-08-31 | Burczynski Michael E | Methods for prognosis and treatment of solid tumors |
| EP1644501B1 (en) * | 2003-07-22 | 2011-01-19 | Ludwig Institute For Cancer Research | Ssx-2 peptides presented by hla class ii molucules |
| CN101001868A (zh) * | 2004-06-17 | 2007-07-18 | 曼康公司 | 表位类似物 |
| KR20070056042A (ko) | 2004-06-17 | 2007-05-31 | 맨카인드 코포레이션 | 에피토프 유사체 |
| EP2371850A3 (en) * | 2005-06-17 | 2012-08-01 | Mannkind Corporation | Epitope analogues |
| AU2007248019B2 (en) * | 2006-05-03 | 2012-10-11 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Chimeric T cell receptors and related materials and methods of use |
| WO2008039694A2 (en) * | 2006-09-26 | 2008-04-03 | St. Jude Children's Research Hospital | Methods and compositions for monitoring t cell receptor diversity |
| US8785601B2 (en) * | 2009-01-28 | 2014-07-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors and related materials and methods of use |
| ES2876176T3 (es) * | 2010-09-21 | 2021-11-12 | The Us Secretary Department Of Health And Human Services Office Of Technology Transfer National Inst | Receptores de células T anti-SSX-2 y materiales relacionados y métodos de uso |
-
2011
- 2011-09-14 ES ES19166061T patent/ES2876176T3/es active Active
- 2011-09-14 JP JP2013529285A patent/JP6133209B2/ja active Active
- 2011-09-14 CN CN201180045492.0A patent/CN103124740B/zh active Active
- 2011-09-14 CA CA2811788A patent/CA2811788C/en active Active
- 2011-09-14 EP EP19166061.2A patent/EP3533802B1/en active Active
- 2011-09-14 WO PCT/US2011/051537 patent/WO2012040012A1/en not_active Ceased
- 2011-09-14 US US13/820,802 patent/US9345748B2/en active Active
- 2011-09-14 EP EP11763819.7A patent/EP2619223B1/en active Active
- 2011-09-14 ES ES11763819T patent/ES2734889T3/es active Active
- 2011-09-14 PT PT11763819T patent/PT2619223T/pt unknown
- 2011-09-14 PT PT191660612T patent/PT3533802T/pt unknown
- 2011-09-14 AU AU2011305817A patent/AU2011305817B2/en active Active
-
2013
- 2013-03-05 IL IL225063A patent/IL225063A/en active IP Right Grant
-
2016
- 2016-04-19 US US15/132,863 patent/US10143724B2/en active Active
-
2017
- 2017-04-19 JP JP2017082965A patent/JP2017158567A/ja active Pending
- 2017-09-13 IL IL254469A patent/IL254469B/en active IP Right Grant
-
2018
- 2018-10-29 US US16/173,701 patent/US10864252B2/en active Active
-
2019
- 2019-11-28 IL IL271021A patent/IL271021B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014500002A5 (cg-RX-API-DMAC7.html) | ||
| Ahn et al. | Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19) | |
| Bielamowicz et al. | Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma | |
| JP2014528714A5 (cg-RX-API-DMAC7.html) | ||
| Li et al. | HIV-1 neutralizing antibodies display dual recognition of the primary and coreceptor binding sites and preferential binding to fully cleaved envelope glycoproteins | |
| JP2023159112A5 (cg-RX-API-DMAC7.html) | ||
| JP2015525208A5 (cg-RX-API-DMAC7.html) | ||
| WO2020069184A2 (en) | Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy | |
| Eliyahu et al. | Antibody repertoire analysis of hepatitis C virus infections identifies immune signatures associated with spontaneous clearance | |
| JP2015535816A5 (cg-RX-API-DMAC7.html) | ||
| JP2018529327A5 (cg-RX-API-DMAC7.html) | ||
| WO2019126464A2 (en) | Compositions and methods for treating hiv/aids with immunotherapy | |
| Salloum et al. | Escape from HLA-B* 08-restricted CD8 T cells by hepatitis C virus is associated with fitness costs | |
| Guo et al. | Effective chimeric antigen receptor T cells against SARS-CoV-2 | |
| CA3184695A1 (en) | T cell antigen receptor, multimeric complex thereof and preparation method and use thereof | |
| Xiong et al. | ACE2-using merbecoviruses: Further evidence of convergent evolution of ACE2 recognition by NeoCoV and other MERS-CoV related viruses | |
| Xie et al. | Novel monoclonal antibodies and recombined antibodies against variant SARS-CoV-2 | |
| Wang et al. | Characterization of RBD-specific cross-neutralizing antibodies responses against SARS-CoV-2 variants from COVID-19 convalescents | |
| Lomakin et al. | Two-dimensional high-throughput on-cell screening of immunoglobulins against broad antigen repertoires | |
| JP2017536821A5 (cg-RX-API-DMAC7.html) | ||
| Ding et al. | Characteristics of the Vδ2 CDR3 sequence of peripheral γδ T cells in patients with pulmonary tuberculosis and identification of a new tuberculosis-related antigen peptide | |
| WO2024114830A1 (zh) | 一种针对新冠病毒rbd的广谱单克隆抗体、其制备方法及应用 | |
| CN114349847B (zh) | 靶向新型冠状病毒rna依赖性rna聚合酶的特异性tcr | |
| Li et al. | A spike-targeting bispecific T cell engager strategy provides dual layer protection against SARS-CoV-2 infection in vivo | |
| Wensel et al. | A novel gp41-binding adnectin with potent anti-HIV activity is highly synergistic when linked to a CD4-binding adnectin |